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Abstract 
Background and Purpose: The B-type natriuretic peptide (BNP1-32) exerts vasorelaxing 
and cardioprotective activity. BNP is used as a biomarker for the diagnosis of 
cardiopathological conditions and recombinant BNP1-32 as a drug for the treatment of such. 
BNP1-32 has a short half-life time and thus, similar to other vasoactive peptides like 
angiotensin II and bradykinin, can be enzymatically truncated forming bioactive metabolites. 
We aimed to investigate the metabolism of BNP1-32 in mouse lung, to identify potential new 
BNP metabolites and to disclose their biological activity compared to the BNP1-32, in vitro 
and in vivo. 
Experimental Approach: Using High Performance Liquid Chromatography and Mass-
Spectrometry, we identified a new BNP metabolite, BNP1-30, in the lung being generated by 
endothelin-converting enzyme-1.  
Key Results: BNP1-30 is more efficient in stimulating the guanylyl cyclase receptor A (GC-
A) and, in contrast to BNP1-32, is also able to profoundly stimulate the GC-B. In vivo, 
BNP1-30 reduced the mean arterial blood pressure of normotensive mice after acute infusion 
significantly more than BNP1-32. In a model of severe hypertension, a 3-day infusion of 
BNP1-30 was able to reduce systolic blood pressure by 30 mmHg and to improve markers of 
heart failure, while BNP1-32 was without significant effect. 
Conclusion and Implications: Our results suggest that BNP1-32 is the precursor for the 
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peptide system. Due to expanded activity, BNP1-30 might be a promising treatment option 
for cardiovascular diseases. Furthermore, its potency as a new diagnostic marker of specific 
cardiac dis ases should be evaluated. 
Keywords: Cardiovascular Disease/Hypertension/Pharmacology/Natriuretic peptides/Peptide 
metabolism 
Abbreviations 
BNP1-32 = B-type natriuretic peptide 1-32; BNP1-30 = B-type natriuretic peptide with 30 
amino acids instead of 32 like in the original BNP1-32; CP = Carboxypeptidase; ECE-1 = 
Endothelin-converting enzyme-1; GC = guanylyl cyclase receptor; HDMEC = Human dermal 
microvascular endothelial cells; HEK293 cells = human embryonal kidney cells; HPLC = 
High Performance Liquid Chromatography, MALDI-TOF-MS = Matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry; MC = mesangial cells; NEP = 
Neprilysin; VSMC = Vascular smooth muscle cells, ZPP = Z-pro-prolinal 
Bullet point summary 
What is already known: 
 BNP1-32 is not the only cardiovascular protective BNP.
What this study adds: 
 BNP1-32 is not the most active BNP peptide in the system, BNP1-30 is more
effective.
Clinical significance: 
 BNP1-30 could be a potential new treatment option or biomarker for specific
cardiovascular diseases.
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Introduction 
Natriuretic peptides are naturally occurring cyclic hormones maintaining natriuresis and 
diuresis leading to reduced blood pressure and vascular volume (Potter et al., 2009). All 





). This intact ring system is the prerequisite for biological activity
(Misono et al., 1984). The biological actions of natriuretic peptides are modulated by three 
different membrane-bound receptor subtypes, guanylyl cyclase receptor A, B, and C (GC-A, 
GC-B, and GC-C) (Potter et al., 2006). A-type natriuretic peptide (ANP) and B-type 
natriuretic peptide (BNP) are ligands of GC-A, while C-type natriuretic peptide (CNP) 
stimulates the GC-B. Both receptors contain an intra-cellular guanylyl cyclase domain, which 
can convert GTP to the second messenger cGMP after stimulation with its native ligands. 
GC-C has similar affinity to all three natriuretic peptides and is commonly considered a 
clearance receptor and is discussed to be involved in cardiovascular diseases (Rubattu et al., 
2010).  
BNP has gained increased importance as a biomarker in the clinical diagnosis of 
cardiovascular diseases, for risk stratification and guidance of therapy, since its plasma levels 
are elevated under such conditions and rise with the progression of the disease (Logeart, 
2010, Korenstein et al., 2007). Moreover, Nesiritide®, the recombinant manufactured mature 
human BNP1-32, has been studied in many clinical trials and is discussed as a drug for the 
intravenous treatment of selected patients with acutely decompensated congestive heart 
failure (O'Connor et al., 2011, Pleister et al., 2011).  
Catabolism of BNP was mainly regarded to be performed by neprilysin (E.C.3.4.24.11), but 
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although they are structurally similar (Walther et al., 2004, Pankow et al., 2009). Compared 
to ANP and CNP, the degradation of BNP is virtually not affected by neprilysin. Instead, we 
identified BNP to be metabolised by meprin A in murine kidney into the N-terminal truncated 
and less biologically active metabolite BNP7-32 (Pankow et al., 2007).  
Materials and Methods 
All human and mouse recombinant BNP metabolites were synthesised by Biosyntan (Berlin, 
Germany). The cGMP ELISA kit for cells or for plasma was purchased from Enzo Life 
Sciences (Loerrach, Germany). Recombinant Endothelin-converting enzyme-1 was 
purchased from R&D Systems (Wiesbaden, Germany). PolyFect® reagent was obtained from 
Qiagen GmbH (Hilden, Germany). GC-A was purchased from Origene Technologies 
(Rockville, Md). GC-B was provided as a gift by Michael Bader (MDC, Berlin, Germany). 
Cell culture products were purchased from Invitrogen (Karlsruhe, Germany). The 
QuantiTect® Reverse Transcription Kit and the QuantiTect® SYBR® Green PCR Kit were 
used from Qiagen GmbH. All other chemicals used were obtained from Sigma (Taufkirchen, 
Germany). Animals were purchased from Charles River® (Sulzfeld, Germany and Margate, 
UK). 
Human and mouse lung preparation 
Human (healthy tissue provided by the University Hospital Giessen) and mouse (C57B/L6J 
[RRID:MGI:5657312]) lung homogenates were prepared by homogenising lung tissue in a 50 
mM Tris buffer (pH 7.4) with a homogeniser. To generate mouse lung membranes, 
homogenised samples were centrifuged at 40,000 g to separate membranes from the cytosol. 
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The total protein content of the membrane preparations was determined by BCA assay and 
adjusted depending on the experiment. 
Degradation of mBNP1-32 by mouse lung membrane preparations  
Ten µM of mBNP1-32 was incubated with murine lung membrane preparations (60 µg 
protein 100 µM buffer) in Tris buffer (50 mM, pH 7.5) supplemented with 0.1% BSA 
(Tris/BSA - buffer) at 37°C under constant shaking at 300 U min
-1
. The buffer was
supplemented with traces of BSA to minimise adhesion of the peptides on the tube walls. 
Reactions were stopped after 0, 20, 40, 60, and 80 min by a pH change with perchloric acid. 
After centrifugation, supernatants were analysed by Liquid Chromatography Mass 
Spectrometry (LCMS) and matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry. 
Degradation of hBNP by human lung preparations 
Ten µM of hBNP1-32 of hBNP1-30 were incubated with human lung homogenate (90 µg 
protein 150 µL buffer) in Tris buffer (50 mM, pH 7.5) with 0.1% BSA (Tris/BSA - buffer) at 
37°C under constant shaking at 300 U min
-1
. The reactions were stopped after 0 and 10 min
by addition of perchloric acid. The samples were then centrifuged and the supernatants were 
analysed by LCMS. For comparison of mBNP1-30 and hBNP1-30 degradation, equal 
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Generation of mBNP1-30 with lung membrane preparations in the presence of enzyme 
inhibitors 
Ten µM of mBNP1-32 were incubated with 60 µg/mL protein of organ membrane 
preparations in Tris/BSA buffer (50 mM pH 7.5) in the presence of the following enzyme 
inhibitors: actinonin against meprin A [10 µM], captopril against Angiotensin-converting 
enzyme [10 µM], Carboxypeptidase inhibitor [10 µM], Chymostatin against serine and 
cysteine peptidases [5 µM], EDTA against metallopeptidases [5 µM], F480 against 
Angiotensin-converting enzyme-2 [1 µM], Leupeptin against serine and cysteine peptidases 
[10 µM], pepstatin against aspartylpeptidases [10 µM], Roche cocktail inhibitor 10x [1 µL], 
SM19712 against endothelin-converting enzyme 1 [10 µM], trypsin inhibitor against trypsin-
like peptidases [10 µM], Z-pro-prolinal against prolylcarboxypeptidases [100 µM] in a 
reaction volume of 100 µL. Samples were incubated at 37°C under constant shaking at 300 U 
min
-1
. Reactions were stopped after 60 min by inducing a pH change by supplementation of
perchloric acid. After centrifugation supernatants were analysed by liquid chromatography 
mass spectrometry and Matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry. 
Degradation of natriuretic peptides by recombinant Endothelin-converting enzyme-1  
Murine ANP, BNP1-32, and CNP were incubated with 0.4 mU of recombinant Endothelin-
converting enzyme-1 in Tris/BSA buffer (50 mM, pH 7.5). Reactions were stopped after 0, 
20, 40, and 60 min by a pH shift with perchloric acid. After centrifugation, supernatants were 
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Liquid Chromatography Mass Spectrometry (LCMS) 
Murine peptide analysis was performed by reversed phase chromatography using an LCMS 
with UV-d tection from Shimadzu (Duisburg, Germany). Each murine sample was loaded 
onto a RP Nucleosil 100 C12 column (250 x 4.6 mm, 5 μm) from Phenomenex 
(Aschaffenburg, Germany) with a flow rate of 1 mL min
-1
. Human samples were analysed
after being injected onto a RP Jupiter Proteo C12 column (250 x 4.6 mm, 4 μm) from 
Phenomenex with a flow rate of 0.5 mL min
-1
. The peptides were detected at 206 nm and a
linear correlation between peak areas and natriuretic peptide concentrations was confirmed 
before analysis. BNP1-32 and its degradation products were eluted within 35 min using a 
linear gradient of acetonitrile and ultrapurified water laced with 0.05% trifluoracetic acid for 
murine samples or 0.10% formic acid for human samples. After separation, peaks were 
manually fractionated for the analysis with matrix-assisted laser desorption/ionisation time-
of-flight mass spectrometry.  
Matrix-Assisted Laser Desorption/ Ionisation Time-of-flight Mass Spectrometry 
(MALDI-TOF MS)  
MALDI-TOF-MS was performed on an Ultraflex I TOF/TOF mass spectrometer equipped 
with a nitrogen laser and a LIFT-MS/MS facility from Bruker Daltonics (Bremen, Germany). 
The instrument was operated in the positive-ion reflectron mode using 2.5-dihydroxybenzoic 
acid and methylendiphosphonic acid as matrix. Sum spectra consisting of 200–400 single 
spectra were acquired. 1 µL of the dried sample was mixed with 1 µL of the matrix dissolved 
in trifluoroacetic acid in acetonitrile-water and placed on the MALDI plate, followed by spot 
analyses. For external calibration a peptide standard from Bruker Daltonics) was used. For 
data processing and instrument control, the Compass 1.1 software package consisting of 
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Cell Culture and transfections 
Human embryonic kidney cells (HEK293 [RRID:CVCL_0045]) were cultured in DMEM 
supplemented with 10% FBS and penicillin–streptomycin (100 IU mL
-1
 to 100 µg mL
-1
). The
cultures were maintained at 37°C in a 5% CO2 humidified incubator. One day after seeding, 
HEK293 cells were transferred into 24-well cell culture dishes. Transfections with plasmids 
encoding murine GC-A or GC-B were performed using PolyFect
®
 reagent in DMEM with
0.5% FBS. Cells transfected with the empty plasmid served as controls. After 24 hours, cells 
were used for bioactivity measurements.  
Human dermal microvascular endothelial cells (Zhu et al., 2013) were cultured in Endothelial 
Cell Basal Medium supplemented with growth factors present in the Endothelial Cell 
Supplement Kit from PromoCell. Vascular smooth muscle cells and mesangial cells were 
isolated from the explants of the thoracic aortas (Zhu et al., 2013) or kidneys (Tetzner et al., 
2016) of 4 to 6-week-old C57BL/6 animals. Vascular Smooth muscle cells were grown in 
DMEM supplemented with 10% FBS, 100 IU mL
-1
 penicillin, and 100 μg mL
-1
 streptomycin
as described previously (Pankow et al., 2007). Kidneys were decapsulated and minced in ice-
cold RPMI medium. Homogenates were dispersed with 5 mL chilled RPMI medium to a 100 
μm nylon filter and then the filtrate transferred to a 70 μm nylon filter. After decapsulated, 
the glomerular ‘cores’ were digested with collagenase type II for approximately 30 min, then 
centrifuged at 1000 rpm for 10 min. The pellet was resuspended in RPMI 1640 medium 
supplemented with 17% FBS, penicillin/streptomycin, and 0.1 U mL
-1
 insulin. The cultures
were placed at 37°C in a humidified 5% CO2 incubator (Tetzner et al., 2016). 
Bioactivity of natriuretic peptides in vitro: 
Transfected HEK293cells, human dermal microvascular endothelial cells, vascular smooth 
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containing 1 µM of the respective natriuretic peptide for 5 min. After washing 3 times in cold 
Hank’s balanced salt solution, cells were resuspended in 150 µL of cell lyses buffer provided 
in a cGMP kit. Concentrations of cGMP were determined according to the instructions of the 
manufacturer and were measured at 405 nm with a correction at 570 nm and expressed as 
picomoles per millilitre as shown previously (Zhu et al., 2013, Pankow et al., 2007, Pankow 
et al., 2009). All experiments have an n of = 3 in triplicates. 
Bioactivity measurement in vivo 
All animals were maintained under standardized conditions with an artificial 12-hour 
dark/light cycle, with free access to food and water. Experiments on animals, blood 
collection, and organ explanations were performed in accordance with the Animals 
(Scientific Procedures) Act 1986 of the Parliament of the United Kingdom, the Federal Law 
on the Use of Experimental Animals in Germany, guidelines from Directive 2010/63/EU of 
the European Parliament on the protection of animals used for scientific purposes. 
Experiments were approved by the local authorities (Home Office, London, UK; 
Regierungspraesidium Giessen, Germany). Human tissue samples were obtained and handled 
in adherence to the principles of the Declaration of Helsinki and Title 45, U.S. Code of 
Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 2001, 
effective December 13, 2001. 
Bioactivity and hemodynamic measurements in mice 
Male C57B/L6J mice (16 weeks, n=26, vehicle arm n=5, mBNP1-30, mBNP1-32, and 
mBNP1-45 arms n=7) were randomised into groups, whereby the experimenter was blinded 
to treatment. Mice were anesthetised with 4% isoflurane and intubated for artificial 










This article is protected by copyright. All rights reserved. 
which 2% to 2.5% isoflurane was added for continuous anaesthesia. During surgery, animals 
were kept on a homoeothermic blanket to maintain body temperature. The right common 
carotid art ry and the right internal jugular vein were dissected. A Mikro-Tip
®
 mouse
pressure catheter from Millar Instruments, Texas was inserted into the carotid artery and a 
cannula was inserted into the jugular vein. Baseline blood pressure and heart rate were 
monitored and recorded for 10 minutes with a pressure transducer system and a blood 
pressure monitoring software from TSE systems GmbH, Germany. Through the cannula, a 
single bolus injection of murine BNP1-32, BNP1-30, BNP1-45 (100 µL 30g
-1
 body weight of
a 5x10
-6
 M solution [1.67 nmol peptide g
-1
 body weight]), or saline was injected. The
hemodynamic parameters were measured for 4 min after injection. Subsequent to the 
measurement, EDTA blood was taken by puncturing of the left ventricle. Blood samples were 
centrifuged, and the plasma was snap frozen in liquid nitrogen and stored at -80°C until 
further processing. Plasma cGMP levels were measured after an extraction process using 
95% ethanol by the cGMP complete ELISA Kit for plasma samples according to the 
manufacturer’s instructions.  
Bioactivity and hemodynamic measurements in spontaneously hypertensive rats (SHR) 
Osmotic minipumps from Alzet, California (pump rate: 0.5 µL hr
-1
) were put into sterile
saline solution for three hours for preconditioning. After that, minipumps were filled each 
with either sterile saline, or filtered solutions of BNP1-32 or BNP1-30 to allow the 




. Male spontaneously hypertensive rats
(RRID:RGD_61000) at the age of 12 weeks (n=18, 6 mice per arm; vehicle, mBNP1-32, and 
mBNP1-30) were randomised into groups, whereby the experimenter was blinded to 
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small part of the fur on the backside was removed using depilatory cream. Next, a primed 
osmotic minipump was implanted under the skin on the backside of the animal. Wounds were 
closed with clips. After the animals woke up, they were kept in appropriate cages with 
normal housing and food for three days. For the determination of hemodynamic parameters, 
animals were anesthetised with 4% isoflurane and were kept ventilated with a mixture of 20% 
oxygen and 80% room air through a rodent ventilator, to which 2% to 2.5% isoflurane was 
added for continuous anaesthesia. Animals were kept on a homoeothermic blanket to 
maintain body temperature. The right common carotid artery was dissected. A Mikro-Tip
®
 rat
pressure catheter from Millar Instruments, Texas was placed into the right carotid artery to 
measure arterial blood pressure and heart rate. Parameters were recorded for 10 minutes with 
a blood pressure monitoring software from TSE systems GmbH, Germany. Finally, EDTA 
blood was taken by puncturing of the left ventricle. Blood samples were centrifuged, and the 
plasma was snap frozen in liquid nitrogen and stored at 193.15K until further processing. 
Plasma cGMP levels were measured using the cGMP complete ELISA Kit for plasma 
samples according to the manufacturer’s instructions.  
Real time PCR 
The quantitative real-time polymerase chain reaction (RT-PCR) was carried out in three steps 
including isolation of RNA, reverse transcription, and SYBR® Green-based RT-PCR. After 
cardiac RNA isolation, 1 µg of RNA was used to transcribe cDNA with the QuantiTect
®
Reverse Transcription Kit from Qiagen according to the manufacturer’s instructions. 





 Green PCR Kit from Qiagen. Melting curve analyses were
performed to monitor PCR product purity. To compare the different treatment groups to the 
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Statistics 
For statistical comparisons, Student’s t test or One-way ANOVA with Bonferroni's Multiple 
Comparison (Graph Pad Prism 5.01 [RRID:SCR_002798]; Graph Pad Software Inc., San 
Diego, California, USA) were used (means ± SEM). Two-way ANOVA was used to compare 
BNP1-32 and BNP1-30 in dose-response curves. Post-hoc tests were only performed if F was 
significant and there was no variance inhomogeneity. EC50 values were calculated by using 
sigmoidal dose response curve fit in (Graph Pad Prism 5.01; Graph Pad Software Inc., San 
Diego, California, USA). Significance was considered at a value of P < 0.05. 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18: G protein‐ coupled receptors (Alexander et 
al., 2017). 
Results and Discussion 
Besides kidney, other organs have a high metabolic activity towards natriuretic peptides. Our 
investigation of the initial metabolism of BNP1-32 in such organs revealed the occurrence of 
another BNP metabolite, generated by an enzyme from murine lung. As seen in Figure 1A, 
BNP1-32 was degraded by lung membrane preparations over time resulting in the generation 
of an initial and dominant cleavage product (Fig. 1B; retention time 12.34 min). This product 
was analysed qualitatively by LCMS and moreover fractionated after LC separation for 
additional analysis by matrix-assisted laser desorption/ionisation time-of-flight mass 
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could be assigned to a C-terminal truncated 30 amino acid long analogue of BNP (Fig. 1C), 
named BNP1-30. Other than in our former investigations in kidney, we did not find a peak of 
BNP7-32 in the chromatograms even upon enhanced incubation times, suggesting that this 
metabolite was not produced in lung. 
With the help of enzyme inhibitors, we aimed to discover the peptidase responsible for 
BNP1-30 generation. Figure 2A shows the amount of BNP1-30 accumulated through 
incubation with membrane preparations of the lung in the presence of enzyme family-specific 
inhibitors (white bars) or enzyme-specific inhibitors (grey bars). The amount of BNP1-30 
generated with the membranes in the absence of peptidase inhibitors was set to 100% (black 
bar). EDTA, a metallopeptidase inhibitor, inhibited the generation of BNP1-30 by 
approximately 50% while other enzyme-family specific inhibitors had no significant 
influence. Therefore, a collection of specific metallopeptidase inhibitors were used and it was 
found that the specific inhibitor for the endothelin-converting enzyme 1, SM-19712, was 
effective in inhibiting BNP1-30 generation. Consequently, generation of BNP1-30 by lung 
membranes was compared over time in the presence or absence of a specific Endothelin-
converting enzyme-1 inhibitor (Fig. 2B). Inhibition of the peptidase clearly reduced 
accumulation of BNP1-30 over time. Subsequently, recombinant Endothelin-converting 
enzyme-1 was incubated with BNP1-32 to investigate whether the peptidase is able to 
generate BNP1-30. As seen in Figure 2C by the overlay of the chromatograms generated 
from incubation of BNP1-32 with lung membrane preparations or with recombinant 
endothelin-converting enzyme-1, a cleavage product with the same retention time was 
generated. For additional proof, the cleavage product from endothelin-converting enzyme-1 
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of-flight mass spectrometry which revealed that the peak indeed represents the metabolite 
BNP1-30.  
To disclose a possible impact of endothelin-converting enzyme-1 on other natriuretic 
peptides, the peptidase was incubated with murine ANP and CNP and its catabolism 
compared towards that of mBNP1-32. The peptidase was not able to cleave the other two 
natriuretic peptides (Fig. 2D).  
As seen in Figure 1C, BNP1-30 still provides the disulphide-linked loop structure, which is 
essential for biological activity of natriuretic peptides (Potter et al., 2009). Thus, we 
hypothesised that BNP1-30 is still bioactive and tested its potency to stimulate GC-A and 
GC-B in transfected HEK293 cells by quantifying the formation of the second messenger 
cGMP. As previously shown (Potter, 2011, Pankow et al., 2007), ANP and BNP stimulated 
their native receptor GC-A, but could not profoundly stimulate the cGMP generation via GC-
B. The same result is seen in Figure 3A&B. The new BNP metabolite BNP1-30 was also 
able to stimulate GC-A (Fig. 3A). Interestingly, the formation of cGMP was significantly 
higher in BNP1-30-stimulated cells compared to BNP1-32-stimulated cells indicating that 
BNP1-30 is more bioactive on the GC-A compared to BNP1-32. This is different to the 
previously identified metabolite BNP7-32 whose ability to stimulate the receptor was only 
half of that compared to BNP1-32 (Pankow et al., 2007). Although ANP and BNP1-32 could 
only marginally stimulate the GC-B, BNP1-30 showed a much more pronounced effect on 
GC-B transfected cells, which was still low, compared to its effect on GC-A, but was 3-fold 
higher in comparison to BNP1-32. Of note, none of the peptides could increase cGMP levels 
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To test whether the cGMP generation stimulated by either GC-A or GC-B can be additive, 
double-transfected HEK293 cells were used. Dose-response curves identified BNP1-30 to be 
more effici nt. A lower half maximal effective concentration (EC50) also indicated a higher 
potency compared to BNP1-32, but this difference was not significant (Fig. 3C). 
Investigation of primary cells being essential in blood pressure and sodium homeostasis 
showed that stimulation of either primary endothelial cells (EC), dominantly expressing 
endogenous GC-A, or mesangial cells, primarily expressing endogenous GC-B, with BNP1-
30 was significantly more efficient compared to stimulation with BNP1-32 (Fig. 3D&E) 
(Zhu et al., 2013). Similar results were observed in vascular smooth muscle cells, expressing 
both receptors (Fig. 3F) (Zhu et al., 2013).  
To evaluate whether the higher efficiency of the new BNP metabolite in a variety of different 
primary cell types correlates to in vivo actions, we first investigated the acute biological 
effect of BNP1-32 and BNP1-30 on blood pressure in a normotensive animal model. In a first 
experiment, each peptide or saline as a control was injected into the jugular vein of wild-type 
mice after ensuring stable baseline blood pressure conditions. Infusion of either BNP1-32 or 
BNP1-30 resulted in a transient decrease in blood pressure compared to saline injection (Fig. 
4A). However, the new metabolite BNP1-30 caused a significant higher decrease in the mean 
arterial blood pressure that was almost doubled compared to that of the mature BNP1-32. 
Notably, the time to reach its maximal vasorelaxant effect was not different between both 
peptides (BNP1-32: 3.8 ± 0.7 min; BNP1-30: 3.3 ± 1.2 min). This physiological effect was 
associated with a more pronounced increase in cGMP levels in the plasma of the BNP1-30-
treated animals compared to the BNP1-32 treated animals (Fig. 4B), strongly supporting our 
in vitro data (Fig. 3). In an independent set of animals, BNP1-30 was compared to BNP1-45, 
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been discussed to be the active BNP fragment in the murine system (Ferdinal et al., 2009, 
Steinhelper, 1993, Nakagawa et al., 1995). Although, again both peptide infusions caused a 
significant decrease in blood pressure compared to the saline infusion, the effect of BNP1-30 
was almost doubled in comparison to BNP1-45 (Fig. 4C).  
Additionally, BNP1-32 and BNP1-30 were tested in a hypertensive animal model to compare 
their blood-pressure lowering effects under pathophysiological conditions. In contrast to the 
experiments in mice, the peptides or saline were administered through an osmotic minipump 
into 3-month old SHR for three days to evaluate longer-lasting blood pressure effects. 
Hemodynamic measurement at the end of the 3 days showed the excessive blood pressure 
elevation described for such SHR (Pacheco et al., 2011) with systolic blood pressure (SBP) at 
193.9 ± 10.8 mmHg in the control group receiving saline. While there was no significant 
effect of BNP1-32 (ΔSBP: -7.6 +/- 4.4 mmHg), the administration of BNP1-30 lowered the 
SBP by 16 % (ΔSBP: -30.6 +/- 6.7 mmHg) (Fig. 5A). Quantitative real time PCR revealed a 
significant reduction of cardiac ANP mRNA in both treatment groups, whereby this effect 
was more pronounced for BNP1-30 treated animals, most probably due to the reduced wall 
tension in the heart achieved through the reduction of blood pressure (Fig. 5B). Such effect 
was even more pronounced for BNP mRNA. Cardiac BNP mRNA levels in BNP1-30-treated 
animals were significantly reduced while BNP1-32 treatment was without effect (Fig. 5C). A 
possible negative feedback mechanism on BNP generation through the administration of 
BNP seems not to be present, since BNP levels are unaltered in BNP1-32-treated animals. 
Since BNP is used as a biomarker for the progression of cardiovascular diseases (Arakawa et 
al., 1994, Davis et al., 1994), the decrease of BNP mRNA through the treatment of BNP1-30 
indicates an improvement of cardiovascular health of the animals. Obviously, this 
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These in vivo results identify BNP1-30, due to its potent actions on blood pressure, as a very 
promising therapy option for the treatment of hypertension. This direct hypotensive action 
might be further pronounced by additional stimulation of long-lasting natriuresis. Although 
the effects of BNP1-30 need to be further investigated in regards to this, its potent impact on 
both natriuretic peptide receptors and thus on blood pressure makes it likely to also exert at 
least the natriuretic properties of the ‘mature’ BNP1-32, which is already used in the therapy 
of congestive heart failure (O'Connor et al., 2011, Pleister et al., 2011). The actions of BNP1-
30 are not only stronger compared to BNP1-32 but also more complex, since the beneficial 
effects of the GC-B signalling pathway are also given through the ability of BNP1-30 
stimulate this receptor. Because of this extended receptor profile, BNP1-30 should be 
considered as a better treatment option in heart failure patients, where GC-A activity is 
significantly decreased and GC-B accounts for the majority of natriuretic peptide-dependent 
activity in the heart (Dickey et al., 2007). Thus, it should be soon evaluated from the clinical 
perspective whether the therapeutic benefits generated with Nesiritide
®
 can be further
improved by the use of BNP1-30.  
However, it could be argued that the BNP1-30 has no clinical importance as it might not be 
present in a human body. While Niederkofler et al. could demonstrate the generation of a 
BNP1-30 peak when incubating hBNP1-32 with human heparin plasma samples 
(Niederkofler et al., 2008), we performed a set of experiments to identify BNP1-30 in the 
human lung. Figs. 6A&B show the retention times and associated mass spectra of 
recombinant human BNP1-32 and BNP1-30, respectively. While the full peak of human 
BNP1-32 was initially present after addition to human lung homogenate, incubation for 10 
min led to a decreased peak area and to the occurrence of (Fig. 6C) another small peak, 
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However, relative to the mouse, much less human BNP1-30 was detected using human lung 
material. To answer the question whether this result is based on less generation or more rapid 
degradation of human BNP1-30, we performed an additional experiment comparing the 
conversion rate of human and murine BNP1-30 in their species-respective lung material. 
After a 10 minute incubation, only 19.6±1.6% of the original human BNP1-30 remained; as 
opposed to the murine BNP1-30, which had 83.9±7.5% remaining. These results indicate that 
the less pronounced BNP1-30 peak in the human system is based on a faster degradation. 
This discovery further justifies the clinical relevance of this study by proving that BNP1-30 is 
present in human and is not limited to the mouse system. 
BNP is an excellent marker to identify patients with cardiac pathology; however, it fails to 
discriminate between different cardiac diseases. It might be mentioned, that levels of BNP 
measured in plasma by commonly used kits (e.g. Triage
®
) do not consist of BNP1-32 only.
The antibodies used in the routine measurements of BNP levels in cardiovascular and 
intensive care medicine cross-react with other molecular forms of BNP, since they detect 
epitopes within the ring structure of the peptides and thus can also detect shorter fragments 
(Korenstein et al., 2007, Nishikimi et al., 2011). Such antibodies can also not distinguish 
between shorter BNP metabolites still having intact 17-aa ring structures and thus bind to 
BNP1-32 as well as to its metabolites, including BNP1-30. At the moment, no antibodies are 
available to specifically detect BNP metabolites. Furthermore, the concentration of single 
BNP metabolites in the blood might be in the low picomolar or even femtomolar range and 
thus very sensitive methods for the detection and quantification of such small quantities of 
single BNP metabolites need to be established. 
However, the generation of such specific antibodies that would allow the detection and 










This article is protected by copyright. All rights reserved. 
metabolite profile for each patient enabling a completely new strategy in cardiovascular 
medicine. The determination of such a metabolite profile might allow the differentiation 
between diverse cardio-pathologies assuming that the etiopathology specifically changes the 
composition of the BNP pool due to differential regulations on the e.g. peptidase level 
leading to altered availability of BNP metabolising enzymes causing a disease-specific 
metabolite fingerprint. 
Conclusion 
Our results suggest that BNP1-32 functions as the precursor for the more biologically active 
BNP1-30. The manipulation of the length of the C-terminus of BNP changes the receptor 
profile, as the endogenously BNP1-30 is, additionally to a significantly stronger stimulation 
of the GC-A compared to BNP1-32, also able to stimulate the second natriuretic peptide 
receptor, GC-B. The stronger ability of stimulating GC-A makes BNP1-30 in general a more 
effective treatment option of cardiovascular disease conditions like hypertension. 
Additionally, its receptor profile also enables a better treatment for heart failure patients. In 
these patients the main BNP1-32 receptor, GC-A, is dramatically downregulated which 
weakened the effectiveness of nesiritide, the recombinant form of BNP1-32, used as a drug 
for the treatment of decompensated heart failure in the clinics. As a result of the higher 
efficacy and unique receptor profile, BNP1-30 is certainly the better treatment option under 
such conditions and a very promising compound for the treatment of a broad variety of life-
threatening cardiovascular diseases. The more effective stimulation opens up completely new 











This article is protected by copyright. All rights reserved. 
Author Contributions 
A.S., Y.W., and X.Z. performed the majority of the laboratory experiments. A.M. provided
follow-up xperiments and language/formatting review. K.P. and W.E.S. performed part of 
the analytical experiments. T.W. designed the study, supervised the research, and oversaw 
statistics and the editing of the manuscript. 
Competing Interests' Statement 
None 
Declaration of transparency and scientific rigour 
This Declaration acknowledges that this paper adheres to the principles for transparent 
reporting and scientific rigour of preclinical research as stated in the BJP guidelines for 
Design & Analysis, and Animal Experimentation, and as recommended by funding agencies, 










This article is protected by copyright. All rights reserved. 
References 
ALEXANDER, S., CHRISTOPOULOS, A., DAVENPORT, A., KELLY, E., MARRION, 
N., PETERS, J., FACCENDA, E., HARDING, S., PAWSON, A., SHARMAN, J., 
SOUTHAN, C., DAVIES, J. & ET AL. 2017. The concise guide to pharmacology 
2017/18: g protein‐ coupled receptors. British Journal of Pharmacology, 174, S17–
S129. 
ARAKAWA, N., NAKAMURA, M., AOKI, H. & HIRAMORI, K. 1994. Relationship 
between plasma level of brain natriuretic peptide and myocardial infarct size. 
Cardiology, 85, 334-40. 
DAVIS, M., ESPINER, E., RICHARDS, G., BILLINGS, J., TOWN, I., NEILL, A., 
DRENNAN, C., RICHARDS, M., TURNER, J. & YANDLE, T. 1994. Plasma brain 
natriuretic peptide in assessment of acute dyspnoea. Lancet, 343, 440-4. 
DICKEY, D. M., FLORA, D. R., BRYAN, P. M., XU, X., CHEN, Y. & POTTER, L. R. 
2007. Differential regulation of membrane guanylyl cyclases in congestive heart 
failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant 
natriuretic peptide receptor in the failing heart. Endocrinology, 148, 3518-22. 
FERDINAL, F., SUYATNA, F. D., WANANDI, S. I. & SADIKIN, M. 2009. Expression of 
B-type natriuretic peptide-45 (BNP-45) gene in the ventricular myocardial induced by
systemic chronic hypoxia. Acta Med Indones, 41, 136-43.
HARDING, S., SHARMAN, J., FACCENDA, E., SOUTHAN, C., PAWSON, A., 
IRELAND, S. & ET AL. 2018. The IUPHAR/BPS Guide to PHARMACOLOGY in 
2018: updates and expansion to encompass the new guide to 
IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091 D1106. 
KORENSTEIN, D., WISNIVESKY, J. P., WYER, P., ADLER, R., PONIEMAN, D. & 
MCGINN, T. 2007. The utility of B-type natriuretic peptide in the diagnosis of heart 
failure in the emergency department: a systematic review. BMC Emerg Med, 7, 6. 
LOGEART, D. 2010. [Role of BNP in heart failure diagnosis]. Rev Prat, 60, 923. 
MISONO, K. S., GRAMMER, R. T., FUKUMI, H. & INAGAMI, T. 1984. Rat atrial 
natriuretic factor: isolation, structure and biological activities of four major peptides. 
Biochem Biophys Res Commun, 123, 444-51. 
NAKAGAWA, M., TANAKA, I., SUGA, S., OGAWA, Y., TAMURA, N., GOTO, M., 
SUGAWARA, A., YOSHIMASA, T., ITOH, H., MUKOYAMA, M. & ET AL. 1995. 
Preparation of a monoclonal antibody against mouse brain natriuretic peptide (BNP) 
and tissue distribution of BNP in mice. Clin Exp Pharmacol Physiol Suppl, 22, S186-
7. 
NIEDERKOFLER, E. E., KIERNAN, U. A., O'REAR, J., MENON, S., SAGHIR, S., 
PROTTER, A. A., NELSON, R. W. & SCHELLENBERGER, U. 2008. Detection of 
endogenous B-type natriuretic peptide at very low concentrations in patients with 
heart failure. Circ Heart Fail, 1, 258-64. 
NISHIKIMI, T., MINAMINO, N. & NAKAO, K. 2011. Diverse molecular forms of plasma 
B-type natriuretic peptide in heart failure. Curr Heart Fail Rep, 8, 140-6.
O'CONNOR, C. M., STARLING, R. C., HERNANDEZ, A. F., ARMSTRONG, P. W., 










This article is protected by copyright. All rights reserved. 
B. M., MCMURRAY, J. J., NIEMINEN, M. S., REIST, C. J., ROULEAU, J. L.,
SWEDBERG, K., ADAMS, K. F., JR., ANKER, S. D., ATAR, D., BATTLER, A.,
BOTERO, R., BOHIDAR, N. R., BUTLER, J., CLAUSELL, N., CORBALAN, R.,
COSTANZO, M. R., DAHLSTROM, U., DECKELBAUM, L. I., DIAZ, R.,
DUNLAP, M. E., EZEKOWITZ, J. A., FELDMAN, D., FELKER, G. M.,
FONAROW, G. C., GENNEVOIS, D., GOTTLIEB, S. S., HILL, J. A.,
HOLLANDER, J. E., HOWLETT, J. G., HUDSON, M. P., KOCIOL, R. D., KRUM,
H., LAUCEVICIUS, A., LEVY, W. C., MENDEZ, G. F., METRA, M., MITTAL, S.,
OH, B. H., PEREIRA, N. L., PONIKOWSKI, P., TANG, W. H., TANOMSUP, S.,
TEERLINK, J. R., TRIPOSKIADIS, F., TROUGHTON, R. W., VOORS, A. A.,
WHELLAN, D. J., ZANNAD, F. & CALIFF, R. M. 2011. Effect of nesiritide in
patients with acute decompensated heart failure. N Engl J Med, 365, 32-43.
PACHECO, B. P., CRAJOINAS, R. O., COUTO, G. K., DAVEL, A. P., LESSA, L. M., 
ROSSONI, L. V. & GIRARDI, A. C. 2011. Dipeptidyl peptidase IV inhibition 
attenuates blood pressure rising in young spontaneously hypertensive rats. J 
Hypertens, 29, 520-8. 
PANKOW, K., SCHWIEBS, A., BECKER, M., SIEMS, W. E., KRAUSE, G. & WALTHER, 
T. 2009. Structural substrate conditions required for neutral endopeptidase-mediated
natriuretic Peptide degradation. J Mol Biol, 393, 496-503.
PANKOW, K., WANG, Y., GEMBARDT, F., KRAUSE, E., SUN, X., KRAUSE, G., 
SCHULTHEISS, H. P., SIEMS, W. E. & WALTHER, T. 2007. Successive action of 
meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res, 101, 875-82. 
PLEISTER, A. P., BALIGA, R. R. & HAAS, G. J. 2011. Acute study of clinical effectiveness 
of nesiritide in decompensated heart failure: nesiritide redux. Curr Heart Fail Rep, 8, 
226-32.
POTTER, L. R. 2011. Natriuretic peptide metabolism, clearance and degradation. FEBS J, 
278, 1808-17. 
POTTER, L. R., ABBEY-HOSCH, S. & DICKEY, D. M. 2006. Natriuretic peptides, their 
receptors, and cyclic guanosine monophosphate-dependent signaling functions. 
Endocr Rev, 27, 47-72. 
POTTER, L. R., YODER, A. R., FLORA, D. R., ANTOS, L. K. & DICKEY, D. M. 2009. 
Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic 
applications. Handb Exp Pharmacol, 341-66. 
RUBATTU, S., SCIARRETTA, S., MORRIELLO, A., CALVIERI, C., BATTISTONI, A. & 
VOLPE, M. 2010. NPR-C: a component of the natriuretic peptide family with 
implications in human diseases. J Mol Med (Berl), 88, 889-97. 
STEINHELPER, M. E. 1993. Structure, expression, and genomic mapping of the mouse 
natriuretic peptide type-B gene. Circ Res, 72, 984-92. 
TETZNER, A., GEBOLYS, K., MEINERT, C., KLEIN, S., UHLICH, A., TREBICKA, J., 
VILLACAÑAS PÉREZ, O. & WALTHER, T. 2016. The G protein-coupled receptor 
MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and 
phosphokinase A. Hypertension, 68, 185-194. 
WALTHER, T., STEPAN, H., PANKOW, K., BECKER, M., SCHULTHEISS, H. P. & 










This article is protected by copyright. All rights reserved. 
independent catabolism of atrial and brain natriuretic peptide. Biol Chem, 385, 179-
84. 
ZHU, X., WANG, Y., SCHWIEBS, A. & WALTHER, T. 2013. Chimeric natriuretic peptide 
ACNP stimulates both natriuretic peptide receptors, the NPRA and NPRB. Mol Cell 










This article is protected by copyright. All rights reserved. 
Figure 1: Identification of a new mBNP metabolite: A) Degradation of mBNP1-32 with 
murine lung membrane preparations over time (n = 3). Remaining concentration of mBNP1-
32 in percent; B) Representative HPLC chromatogram of mBNP1-32 and product peak after 
20 min incubation with murine lung membrane preparations; C) conducted secondary 
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Figure 2: Investigation of the peptidase responsible for the generation of the new 
metabolite mBNP1-30: A) mBNP1-30 generation within 60 min through enzyme activity in 
lung membrane preparations with or without the presence of enzyme inhibitors. Generation 
of mBNP1-30 without inhibitors was set to 100% (black bar); B) Generation of mBNP1-30 
using lung membrane preparations with and without the specific ECE-1 inhibitor SM19712 
over time; generation of mBNP1-30 at 120 min was set to 100%; C) overlay of HPLC 
chromatograms of BNP1-32 and product peak (BNP1-30) after incubation of BNP1-32 with 
recombinant ECE-1 (in red) or after incubation with murine lung membrane preparations (in 
black). D) Metabolism of murine ANP, BNP, and CNP by recombinant ECE-1 over time; 
Where error bars are not indicated, SEM is within data symbols. (n = 3 in triplicates). 
Abbreviations: trp.inhib. = trypsin inhibitor, CP inhib. = carboxypeptidase inhibitor, mANP = 
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Figure 3: Comparison of natriuretic peptides’ bioactivity in vitro: A) cGMP levels [pmol 
mL
-1
] after stimulation of GC-A-transfected HEK cells using 10
-6 
M of the peptides; B)
cGMP levels [pmol mL
-1
] after stimulation of GC-B-transfected HEK cells with 10
-6
 M of the
peptides; C) dose-response-curve of stimulated GC-A & GC-B double-transfected HEK cells; 
D) levels of cGMP [pmol mL
-1
] after stimulation of MC; E) levels of cGMP [pmol mL
-1
]
after stimulation of human dermal microvascular endothelial cells; F) levels of cGMP [in
percent] after stimulation of primary VSMC (D-F: peptide concentration of 10
-6
 M); Where
error bars are not indicated, SEM is within data symbols. (n = 3 in triplicates). Abbreviations: 
mANP=murine atrial natriuretic peptide, mBNP=murine B-type natriuretic peptide, 
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Figure 4: Acute influence of mBNP peptides on blood pressure in normotensive animal 
models: A) Blood pressure delta [mmHg] after bolus injection of mBNP1-32 or mBNP1-30 
(100 µL 30g
-1
 body weight of a 5x10
-6
 M solution [1.67 nmol peptide g
-1
 body weight]) in
comparison to saline in an acute phase experiment in a normotensive mouse model; B) cGMP 
levels [pmol cm
-3
] in plasma samples obtained from mBNP1-32-, mBNP1-30- and saline-
injected animals; C) Acute blood pressure changes [mmHg] in an independent set of 
normotensive mice using mBNP1-45, mBNP1-30, or saline. (n = 7 per peptide, n = 5 for 
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Figure 5: Long-term influence of BNP peptides on the blood pressure in a hypertensive 
animal model: A) Change in systolic blood pressure [mmHg] in spontaneously hypertensive 
rats after continuous administration of mBNP1-32, mBNP1-30, or saline for three days; B) 
Cardiac ANP mRNA levels, and C) Cardiac BNP mRNA levels in fold change in the 
spontaneously hypertensive rats after administration of mBNP1-32, mBNP1-30 or saline for 
three days. (n = 6 per peptide or saline) (* P<0.05 vs. control; # P<0.05 vs. BNP1-32). 
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Figure 6: Generation of hBNP1-30 from hBNP1-32 in human lung homogenate: A) 
Representative HPLC chromatogram and mass spectrum of pure hBNP1-32 peptide. B) 
HPLC chromatogram and mass spectrum of pure hBNP1-30 peptide. C) HPLC 
chromatogram and mass spectrum after 0 minutes of incubation with hBNP1-32. D) HPLC 
chromatogram and mass spectra after a 10-minute incubation with hBNP1-32. 
